Werewolf Therapeutics (NASDAQ:HOWL) Downgraded by Zacks Research to Hold

Werewolf Therapeutics (NASDAQ:HOWL) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday, Zacks reports.

Several other equities research analysts have also commented on the stock. Weiss Ratings upgraded shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics has a consensus rating of “Hold” and an average target price of $4.00.

Werewolf Therapeutics Trading Up 1.9%

HOWL opened at $1.09 on Tuesday. Werewolf Therapeutics has a 12-month low of $0.27 and a 12-month high of $1.27. The business’s fifty day simple moving average is $0.98 and its 200-day simple moving average is $0.69. The company has a market capitalization of $52.97 million, a price-to-earnings ratio of -1.43 and a beta of 0.55.

Institutional Trading of Werewolf Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vilga Financial Planning LLC purchased a new position in shares of Werewolf Therapeutics in the 3rd quarter valued at about $49,000. StoneX Group Inc. raised its stake in shares of Werewolf Therapeutics by 174.3% during the 3rd quarter. StoneX Group Inc. now owns 54,856 shares of the company’s stock worth $51,000 after buying an additional 34,856 shares during the period. Vontobel Holding Ltd. purchased a new position in Werewolf Therapeutics during the third quarter valued at $55,000. BlackRock Inc. purchased a new position in Werewolf Therapeutics in the 2nd quarter valued at about $37,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $37,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues.

Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.